[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642256":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":40,"locations":47,"responsibleParty":69,"collaborators":72,"id":75,"slug":45,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":45,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":45,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":98,"whyStopped":45,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oliceridine Group","EXPERIMENTAL","Participants will receive intravenous oliceridine 0.05 mg\u002Fkg (elderly patients aged ≥65 years) or 0.06 mg\u002Fkg (younger patients aged 18-64 years), administered as a 2-second bolus injection. Cough will be observed for 2 minutes after injection, after which anaesthesia induction will be completed with propofol and rocuronium , followed by tracheal intubation.",[13],"Drug: Oliceridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Sufentanil Group","ACTIVE_COMPARATOR","Participants will receive intravenous sufentanil 0.4 μg\u002Fkg (elderly patients aged ≥65 years) or 0.5 μg\u002Fkg (younger patients aged 18-64 years), administered as a 2-second bolus injection. Cough will be observed for 2 minutes after injection, after which anaesthesia induction will be completed with propofol and rocuronium , followed by tracheal intubation.",[19],"Drug: Sufentanil",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oliceridine","Oliceridine is administered as a single intravenous bolus over 2 seconds at a dose of 0.05 mg\u002Fkg in elderly patients (aged ≥65 years) or 0.06 mg\u002Fkg in younger patients (aged 18-64 years), immediately before propofol and rocuronium for anaesthesia induction.",[9],[27,28],"TRV130","Oliceridine Fumarate",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Sufentanil","Sufentanil is administered as a single intravenous bolus over 2 seconds at a dose of 0.4 μg\u002Fkg in elderly patients (aged ≥65 years) or 0.5 μg\u002Fkg in younger patients (aged 18-64 years), immediately before propofol and rocuronium for anaesthesia induction.",[15],[34],"Sufentanil Citrate",[36],{"name":37,"affiliation":38,"role":39},"Shiyou Wei","Tongji University Affiliated Shanghai Pulmonary Hospital","STUDY_CHAIR",[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Shiyou Wei, MD.","CONTACT","15601680288",null,"lovewishyou@tongji.edu.cn",[48],{"facility":49,"status":45,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Tianmen First People's Hospital","Tianmen","Hubei","431700","China",{"type":55,"coordinates":56},"Point",[57,58],113.15369,30.65888,{"lat":58,"lon":57},[61,65],{"name":62,"role":43,"phone":63,"phoneExt":45,"email":64},"Jianmang Yu, Doc","8613094293728","yujianmang@hbust.edu.cn",{"name":66,"role":43,"phone":67,"phoneExt":45,"email":68},"Zhixiong Xiang, Doc","86-0728-5237400","28612363@qq.com",{"type":70,"investigatorFullName":37,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"SPONSOR_INVESTIGATOR","Department of Anesthesiology",[73],{"name":49,"class":74},"UNKNOWN","100642256",false,"NCT07660380","Oliceridine vs Sufentanil for Cough During Anesthesia Induction","Oliceridine vs Sufentanil for Cough During General Anesthesia Induction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 99 years.\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III.\n* Body mass index (BMI) between 18.5 and 28.0 kg\u002Fm².\n* Scheduled for elective surgery under general anaesthesia.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative upper respiratory tract infection symptoms (e.g., cough, expectoration, or fever) or a history of bronchial asthma or other conditions associated with increased airway reactivity.\n* Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, or serious arrhythmia) or hepatic or renal dysfunction.\n* Long-term opioid use, defined as continuous opioid use for more than 2 weeks within the 3 months prior to surgery.\n* Known hypersensitivity to any study drug or anaesthetic agent used in this protocol.\n* Anticipated difficult airway requiring awake intubation.\n* Pregnancy or breastfeeding.","ALL","18 Years","99 Years",{"count":85,"type":86},62,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","Sufentanil is the most widely used opioid analgesic for general anaesthesia induction; however, rapid intravenous bolus injection frequently triggers sufentanil-induced cough (SIC). In high-risk patients, SIC can cause abrupt elevation of intracranial and intraocular pressure and severe haemodynamic instability, posing a meaningful safety risk during the induction period.\n\nOliceridine, the first G protein-biased μ-opioid receptor agonist approved by the Food and Drug Administration in 2020, provides analgesia through μ-receptor activation while substantially reducing β-arrestin-2 recruitment. This biased signalling profile is hypothesised to raise the excitation threshold of airway C-fibres and thereby reduce the incidence of cough.\n\nThis prospective, single-centre, randomised, double-blind, parallel-group controlled trial directly compares oliceridine with sufentanil for general anaesthesia induction with respect to cough incidence, cough severity, haemodynamic responses, and perioperative safety, with the aim of providing evidence-based guidance for opioid selection during induction.",[92,93],"Cough","Anesthesia",[23,30,95,96,97],"Sufentanil-induced cough","G protein-biased agonist","Anesthesia induction","NOT_YET_RECRUITING","2026-06-18",{"date":101,"type":102},"2026-06-23","ACTUAL",{"date":104,"type":86},"2026-06-22",{"date":106,"type":86},"2026-07-01",{"name":37,"class":6},1]